-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-217 in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-217 in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-217 in Prostate Cancer Drug Details: PT-217 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-217 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-217 in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-217 in Small-Cell Lung Cancer Drug Details: PT-217 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-217 in Neuroendocrine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-217 in Neuroendocrine Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-217 in Neuroendocrine Cancer Drug Details: PT-217 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-217 in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-217 in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-217 in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) Drug Details: PT-217 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belzutifan in Gastrointestinal Stromal Tumor (GIST)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belzutifan in Gastrointestinal Stromal Tumor (GIST) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belzutifan in Gastrointestinal Stromal Tumor (GIST) Drug Details: Belzutifan...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belzutifan in Pheochromocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belzutifan in Pheochromocytoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belzutifan in Pheochromocytoma Drug Details: Belzutifan (Welireg) is an anti-cancer agent. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belzutifan in Paraganglioma (Glomus Jugulare Tumor)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belzutifan in Paraganglioma (Glomus Jugulare Tumor) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belzutifan in Paraganglioma (Glomus Jugulare Tumor) Drug Details: Belzutifan (Welireg)...
-
New
Likelihood of Approval and Phase Transition Success Rate Model – PT-150 in Alcohol Dependence
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-150 in Alcohol Dependence report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-150 in Alcohol Dependence Drug Details: PT-150 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PT-217 in Neuroendocrine Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PT-217 in Neuroendocrine Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PT-217 in Neuroendocrine Carcinoma Drug Details: PT-217 is under development for the...
-
Sector Analysis
Ammonia Industry Capacity and Capital Expenditure Forecasts with Details of Active and Planned Plants to 2028
Ammonia Industry Capacity & CapEx Overview The ammonia industry capacity was 240.38 million tonnes per annum (mtpa) in 2023 and will grow at an AAGR of more than 5% during 2023-2028. Around 113 planned and announced plants are scheduled to start operations by 2028, primarily in North America and FSU to meet the growing demand for nitrogen-based fertilizers in the agriculture industry. Additionally, the elevating cost of feedstock natural gas and the rise of end-users with decarbonization goals are factors...